# FoRx Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/forx-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.forxtherapeutics.com/
- Total disclosed funding: $60M
- Latest round: Series A (Dec 8, 2025)
- Investors on record: 5

## About

Based in Switzerland, and founded in 2019, FoRx Therapeutics AG focuses on developing therapeutic compounds that target key molecular pathways in cancer treatment. In December 2025, FoRx Therapeutics AG raised EUR 42 million in series A funding from returning investors EQT Life Sciences, M Ventures, Novartis Venture Fund and Pfizer Venture Investments. Other unspecified investors also participated in the round. As of January 2026, Tarig Bashir is Chief Executive Officer (CEO) of the company.
FoRx Therapeutics specializes in the development of first-in-class compounds targeting key molecular pathways involved in DNA replication stress, a novel approach in the field of cancer treatment. The company is focused on creating targeted anticancer drugs that address the critical challenges associated with DNA Damage Response pathways. These compounds are primarily aimed at oncologists and healthcare institutions seeking innovative treatments for various types of cancer, with the potential to enhance patient outcomes through more effective therapeutic options. Currently, FoRx Therapeutics is engaged in the early stages of drug development, and while specific product names and release dates are not disclosed, the company is poised to serve markets in North America and Europe, where there is a significant demand for advanced cancer therapies.
FoRx Therapeutics operates on a business model that involves partnerships with pharmaceutical companies and research institutions to advance its drug development initiatives. Revenue generation is anticipated through collaborations that may include licensing agreements, research funding, and milestone payments tied to the successful progression of clinical trials for their compounds. Given the innovative nature of their offerings, the company is expected to engage in B2B transactions, collaborating with healthcare providers and oncology specialists who will administer these therapies to patients. Specific pricing plans or details regarding transaction structures have not been disclosed, but the focus on developing targeted compounds suggests a framework that supports strategic alliances within the biopharmaceutical industry.
The company plans to use the December 2025 funding to conduct early clinical trials of its PARG inhibitor and cover the costs needed to obtain initial patient data.

## Funding rounds

- Series A, Dec 8, 2025, $49M — Novartis Venture Fund, EQT Life Sciences, M Ventures, Pfizer Venture Investments
- Seed, Jun 1, 2019, $11M — Novartis Venture Fund, EQT Life Sciences, Omega Funds, Pfizer Venture Investments, M Ventures

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed, Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Seed, Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Seed
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Seed, Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Seed, Series A